[Form 3] Parabilis Medicines, Inc. Initial Statement of Beneficial Ownership
Rhea-AI Filing Summary
Parabilis Medicines, Inc. insiders associated with Deerfield entities filed an initial Form 3 reporting indirect ownership of multiple preferred stock series that are convertible into voting common stock. The reported holdings are through Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund III, L.P., with general partners and investment manager entities also listed as reporting persons.
The filing shows Series A, B, C and D Preferred Stock positions, each convertible into voting common stock at fixed ratios and at a conversion price of $0.0000 per share. According to the disclosure, each preferred share will automatically convert into common stock upon the closing of the company’s initial public offering of common stock, after giving effect to a 1‑for‑1.5389 reverse split completed on June 3, 2026.
The reporting persons state that, for Section 16 purposes, they disclaim beneficial ownership of the issuer’s securities except to the extent of any indirect pecuniary interest. The positions are therefore characterized as indirect holdings through the Deerfield funds rather than direct personal ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Preferred Stock | -- | -- | -- |
| holding | Series A Preferred Stock | -- | -- | -- |
| holding | Series B Preferred Stock | -- | -- | -- |
| holding | Series B Preferred Stock | -- | -- | -- |
| holding | Series C Preferred Stock | -- | -- | -- |
| holding | Series C Preferred Stock | -- | -- | -- |
| holding | Series D Preferred Stock | -- | -- | -- |
| holding | Series D Preferred Stock | -- | -- | -- |
Footnotes (1)
- Each share of Series A Preferred Stock is convertible into approximately 0.7406 shares of the Issuer's voting common stock (on an adjusted basis after giving effect to the 1-for-1.5389 reverse split of the Issuer's common stock effected by the Issuer on June 3, 2026) and will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock. Each share of Series B Preferred Stock is convertible into approximately 1.0389 shares of the Issuer's voting common stock (on an adjusted basis after giving effect to the 1-for-1.5389 reverse split of the Issuer's common stock effected by the Issuer on June 3, 2026) and will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock. Each share of Series C Preferred Stock is convertible into approximately 1.0578 shares of the Issuer's voting common stock (on an adjusted basis after giving effect to the 1-for-1.5389 reverse split of the Issuer's common stock effected by the Issuer on June 3, 2026) and will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock. Each share of Series D Preferred Stock is convertible into approximately 0.8764 shares of the Issuer's voting common stock (on an adjusted basis after giving effect to the 1-for-1.5389 reverse split of the Issuer's common stock effected by the Issuer on June 3, 2026) and will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock. This Form 3 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield Innovations" and together with Fund III, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P In accordance with Instruction 5 (b)(iv) to Form 3, the entire amount of the Issuer's securities held by the Fund is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.